Dixon Hughes Goodman Wealth Advisors’s Neurogene NGNE Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$0	Buy	+5	New	+$292	﹤0.01%	1012

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's NGNE Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in Neurogene (NGNE) in Q1 2022: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1012 among its holdings.

81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 5 shares of Neurogene worth $0 as of Q1 2022.
Neurogene was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
Neurogene made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #1012 holding.
81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.